Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infant formula meeting canceled

This article was originally published in The Tan Sheet

Executive Summary

FDA Food Advisory Committee meeting on infant formula scheduled for June 20-21 was canceled due to unavailability of some speakers, agency says. Meeting was to be second in series on quality issues ("1The Tan Sheet" June 3, 2002, In Brief). Rescheduling is planned, but dates have yet to be determined...

You may also be interested in...



FAC infant formula, take two

FDA's Food Advisory Committee will meet June 20-21 to discuss "scientific issues and principles involved in assessing and evaluating whether a 'new' infant formula supports normal physical growth in infants when consumed under its intended conditions of use." Meeting is second in a series to assess infant formula quality issues; first took place April 4-5 (1"The Tan Sheet" April 8, 2002, p. 3). FAC will meet at the Holiday Inn, 1000 Baltimore Ave., College Park, Md. For more information, contact CFSAN's Constance Hardy at (301) 436-1433...

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS094179

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel